Amlodipine with atorvastatin (Caduet) for dyslipidaemia with concomitant hypertension or angina
Published in NPS RADAR
Date published: About this date
Clinical content may change after this date. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment.
(am-LOD-i-peen with a-TOR-va-stat-in)
- Amlodipine with atorvastatin (Caduet) is a fixed-dose combination preparation pairing drugs to treat different indications concurrently — hypertension or angina, and dyslipidaemia.
- Do not initiate antihypertensive, anti-angina and/or statin therapy with the combination preparation.
- Establish the effective and tolerated dose of each component as single drugs before changing to the combined preparation.
- Before prescribing, ask ‘Would these be the drugs of choice as individual agents?’ A combination preparation can cost patients less but this should not be the primary consideration.
- For patients responding well to therapy with other drugs there is no reason to change to this fixed-dose combination.
- Do not prescribe Caduet unless the patient has previously tolerated amlodipine 5 mg daily. There is no dose strength of Caduet equivalent to amlodipine 2.5 mg — this is the recommended starting dose in frail, small or elderly people, or in those at risk of hypotension.
- Be aware of the potential for confusion that may arise with the differently named medicine and its eight different dose combinations. Explain to the person being treated which medicines are being replaced by Caduet and tell them to discard any unneeded medicines.
Amlodipine with atorvastatin fixed-dose combination (Caduet) can be prescribed for people with hypertension and/or angina who also meet the Pharmaceutical Benefits Scheme lipid-lowering criteria.
The restriction allows a dihydropyridine calcium-channel blocker to be prescribed*:
- in place of a currently prescribed dihydropyridine calcium-channel blocker (amlodipine [Norvasc], felodipine [Plendil, Felodur], lercanidipine [Zanidip], nifedipine [e.g. Adefin, Adalat])
- in addition to another antihypertensive and/or anti-anginal agent when hypertension or angina are inadequately controlled
- instead of another antihypertensive and/or anti-anginal agent whose adverse effects are poorly tolerated.2
The listing does not allow for prescribing to treatment-naive patients with hypertension and/or angina.
*Dihydropyridine calcium-channel blockers differ from non-dihydropyridine calcium-channel blockers (verapamil and diltiazem) in their sites of action, and their therapeutic and adverse effects. They are therefore not interchangeable.1
Reason for PBS listing
Caduet was listed on the basis of cost minimisation compared with amlodipine and atorvastatin as separate medicines. Costs and efficacy of other antihypertensive–statin combinations were not considered as part of this listing.3
Place in therapy
Caduet is a new type of fixed-dose combination preparation that combines drugs to treat two or more different indications concurrently — hypertension and/or angina with dyslipidaemia. The usual considerations that apply to combination preparations remain important (see Principles of using fixed-dose combination preparations).4
Caduet as fixed-dose combination therapy
Choose antihypertensive and lipid-modifying therapy according to the clinical needs of the individual rather than possible compliance, convenience or cost advantages of the combined preparation. Out-of-pocket costs for the patient will be lower with Caduet than with amlodipine and atorvastatin as separate medicines. However, for patients who are responding well to another antihypertensive–statin combination there is no reason to change to Caduet.
A potential but unproven compliance benefit does not override therapeutic considerations. Compliance is influenced by individual patient characteristics5 as well as the total number of drugs or doses in the regimen.5,8 Simplifying dosage regimens can improve compliance, but the evidence suggests a small relative improvement of between 8% and 20%.9 There are multiple other strategies for improving compliance in patients for whom this is known to be a problem (e.g. exploring the reasons for non-compliance, increased follow-up, patient education, using dose administration aids such as Webster packs).10
Do not initiate amlodipine or atorvastatin therapy with Caduet. Establish the dose of each drug that is effective and well tolerated using the single medicines, before prescribing the combination (see Box 1).
Amlodipine as an antihypertensive agent
Amlodipine is a dihydropyridine calcium-channel blocker; these drugs are considered one of several reasonable first-line choices in uncomplicated hypertension, when there are no compelling indications for using another drug (e.g. coexisting conditions or the need for target-organ protection).11–13 Blood pressure control has a more important effect on cardiovascular outcomes than the class of antihypertensive used.12,14
In head-to-head clinical outcome trials, calcium-channel blockers have been associated with an increased risk of new heart failure compared with ACE inhibitors and thiazide diuretics.14–16 Use amlodipine with caution in people with existing chronic heart failure.17
Calcium-channel blockers vary in their therapeutic effects and individual adverse-effect profiles; consider this if changing to Caduet from a dihydropyridine calcium-channel blocker other than amlodipine. Substitute amlodipine as an individual drug first, to establish dose and tolerance before introducing the combination.
Atorvastatin compared with other statins
For most patients with hyperlipidaemia, the aim of therapy is to reduce low-density lipoprotein–cholesterol (LDL-C) levels to recommended targets. There is no reason to choose atorvastatin over other statins for initiating statin therapy because equipotent doses of statins achieve similar reductions in cholesterol levels. A change to atorvastatin might be considered when maximally tolerated doses of pravastatin or simvastatin do not reduce cholesterol levels sufficiently in patients who are compliant with statin therapy; atorvastatin is more potent in lowering LDL-C levels on a milligram-for-milligram basis than simvastatin or pravastatin18 (see the NPS RADAR review of atorvastatin).
There are no head-to-head trials comparing the effects of atorvastatin with those of equipotent doses of other statins on clinical outcomes.
Principles of using fixed-dose combination preparations
Box 1 lists the uses of Caduet that are consistent with quality use of medicines principles for combined preparations. Think about the questions in Table 1 when assessing the usefulness of any fixed-dose combination preparation.
Box 1: Which uses of Caduet are consistent with quality use of medicines (QUM)?
QUM-recommended use of Caduet
Non-recommended uses of Caduet (according to QUM)
Questions to ask about fixed-dose combination preparations
|Questions to ask||Answer for Caduet|
|Is it a sensible combination?|
|Is the dosing compatible?|
|What will be the impact on adverse effects?|
|What is the place in therapy of the combination preparation?|
|What is the potential for confusion and medication error?|
* There are some occasions when prescribing of a combination preparation as initial therapy is necessary — for example, combined oral contraceptive preparations, some combination antibiotics, some medicines for Parkinson’s disease
There are no apparent differences in adverse effects with Caduet compared with its individual components. The most common treatment-related adverse effects with the combination are peripheral oedema (7%), myalgia (2%) and headache (2%).19
It may be difficult for healthcare providers who are unfamiliar with a patient to determine which of the 8 strengths of Caduet they are taking (e.g. after hospital admission or discharge). Patients who move frequently between different healthcare providers might be at greater risk of error.
Report suspected adverse reactions to the Adverse Drug Reactions Advisory Committee (ADRAC) online or by using the 'Blue Card' distributed with Australian Prescriber. For information about reporting adverse drug reactions, see the Therapeutic Goods Administration website.
Caduet should not be used unless the patient has previously tolerated amlodipine 5 mg or more. There is no Caduet dose strength equivalent to amlodipine 2.5 mg; this dose is often used as a starting dose and is the recommended starting dose in small, frail or elderly people, or those at risk of hypotension.20
Caduet tablets should not be halved.
A disadvantage of fixed-dose combination tablets is that to change the dose of one component a different strength preparation must be prescribed (see Information for patients).
Dose strengths of Caduet available*
|5 mg/10 mg
5 mg/20 mg
5 mg/40 mg
5 mg/80 mg
|10 mg/10 mg
10 mg/20 mg
10 mg/40 mg
10 mg/80 mg
* The strength is marked on the pack, but not on the tablets
Information for patients
Advise patients which of their existing medicines (if any) are being replaced by Caduet and tell them to discard these unneeded medicines to avoid double dosing. There is potential for confusion because:
- Caduet has a completely different brand name to either of its components (amlodipine [Norvasc], atorvastatin [Lipitor])
- changes in strength may not be obvious to the patient because of similarities in the appearance of tablets, which are coloured according to the amlodipine strength.
Tell patients which active ingredients their medicines contain and their strengths, rather than relying on brand names. Encourage patients to carry a medicines list and keep it up to date.
Patients prescribed amlodipine (Norvasc) incur an additional cost because of a Therapeutic Group premium with Norvasc; this cost does not apply to Caduet.3
Suggest or provide the Caduet consumer medicine information (CMI) leaflet. Search for the CMI on the NPS website.
- Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2006.
- Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits, 1 December, 2006.
- Pfizer Australia Pty Ltd. Personal communication, July 2006.
- Moulds RFW. Combination products — love them or loathe them? Australian Prescriber 2001;24:127–9.
- Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006;151:185–91. [PubMed]
- Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147–52. [PubMed]
- George J, Vuong T, Bailey MJ, et al. Medication regimen complexity and adherence in patients at risk of medication misadventure. Journal of Pharmacy Practice and Research 2006;36:99–102.
- Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9:2–6. [PubMed]
- Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004:CD004804. [PubMed]
- Schedlbauer A, Schroeder K, Peters TJ, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2004:CD004371. [PubMed]
- Cardiovascular Writing Group. Therapeutic Guidelines: Cardiovascular. Version 4. Melbourne: Therapeutic Guidelines Ltd, 2003.
- National Heart Foundation of Australia. Hypertension management guide for doctors 2004. Canberra: National Heart Foundation of Australia, 2003.
- New Zealand Guidelines Group. New Zealand Cardiovascular Guidelines. Evidence-based best practice guidelines. Handbook for primary care practitioners. Wellington: New Zealand Guidelines Group, 2005. http:/
/ www. nzgg. org. nz (accessed 29 August 2006).
- Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004–BHS IV. J Hum Hypertens 2004;18:139–85. [PubMed]
- National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care. London: Royal College of Physicians, 2006. http:/
/ www. nice. org. uk/ page. aspx?o=CG034fullguideline (accessed 29 August 2006).
- Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–97. [PubMed]
- Pfizer Australia Pty Ltd. Caduet product information. 14 July 2005.
- National Prescribing Service. Atorvastatin (Lipitor) for the management of lipid disorders. NPS RADAR. 2005 (Dec). http:/
/ www. npsradar. org. au/ site. php?page=1&content=/ npsradar/ content/ atorvastatin. html (accessed 19 September 2006).
- Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) 2005;7:264–73. [PubMed]
- Pfizer Australia Pty Ltd. Norvasc product information. 7 January 2005.